Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Peace Venture Capital 168 Co. Ltd. focuses its company patent portfolio on the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This 1 pending office action is assigned to 1 distinct examiner, which means the company's current prosecution is focused on a single point of contact. The data indicates that this activity is concentrated within 1 distinct art unit, reflecting a specific technical focus for the pending matter.
PALLAY, MICHAEL B is the busiest examiner for the company. This examiner is responsible for 1 busiest examiner pending office action. Because there is only 1 pending office action total, this examiner handles all active matters for the portfolio. The prosecution strategy for this company patent portfolio is currently tied to the decisions of this individual within the Biotechnology & Pharmaceuticals sector. Practitioners must focus their efforts on addressing the specific concerns raised by this examiner. The presence of 1 distinct art unit and 1 distinct examiner indicates a very narrow and targeted presence in the current patent landscape for this entity. This structure allows for a highly specialized approach to securing patent protection.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALLAY, MICHAEL B | 1 | 55.8% | +33.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838548 | NKT CELL LIGAND-CONTAINING LIPOSOME COMPOSITION | PALLAY, MICHAEL B | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838548 | NKT CELL LIGAND-CONTAINING LIPOSOME COMPOSITION | PALLAY, MICHAEL B | 1617 | §103 | Final Rejection | — | Pending | Aug 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPeace Venture Capital 168 Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael B Pallay has the most, with 1 of Peace Venture Capital 168 Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
